Valuation: Edesa Biotech, Inc.

Market Cap 62.33M 54.61M 50.35M 46.53M 88.22M 5.94B 89.69M 601M 236M 2.93B 234M 229M 10.08B P/E 2026 *
-4.22x
P/E 2027 * -3.49x
Enterprise Value 62.33M 54.61M 50.35M 46.53M 88.22M 5.94B 89.69M 601M 236M 2.93B 234M 229M 10.08B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
79.78%
Yield 2026 *
-
Yield 2027 * -
1 day-0.14%
1 week-6.53%
Current month-13.78%
1 month+34.55%
3 months+26.99%
6 months+367.33%
Current year+393.66%
1 week 6.91
Extreme 6.91
7.68
1 month 5.55
Extreme 5.55
8.89
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2015
Director of Finance/CFO 57 01/05/2025
President 48 07/06/2019
Director TitleAgeSince
Chairman 50 07/06/2019
Director/Board Member 55 07/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap.
02/07Free

Founder

3,378 0.0380%
16/06Free

Founder

153,550 1.7268%
16/06Sell

Founder

153,530 1.7266%
Change 5-day change 1-year change 3-year change Capi.($)
-0.14%-6.53%+238.65%+23.63% 62.33M
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
Average -0.62%-0.90%+72.74%+134.79% 24.13B
Weighted average by Cap. -0.91%-1.46%+55.09%+137.75%

Financials

2026 *2027 *
Net sales - -
Net income -14.54M -12.74M -11.74M -10.85M -20.57M -1.39B -20.92M -140M -55.02M -683M -54.57M -53.39M -2.35B -26.51M -23.23M -21.42M -19.79M -37.52M -2.53B -38.15M -256M -100M -1.25B -99.54M -97.38M -4.29B
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
17
Date Price Change Volume
10/07/26 USD 7.010 -0.14% 50,608
09/07/26 USD 7.020 -3.97% 66,626
08/07/26 USD 7.310 +0.14% 29,365
07/07/26 USD 7.300 +1.25% 60,093
06/07/26 USD 7.210 -3.87% 65,719
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.010USD
Average target price
16.33USD
Spread / Average Target
+133.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock